uniQure (QURE) Non-Current Deferred Tax Liability (2021 - 2026)
uniQure's (QURE) quarterly Non-Current Deferred Tax Liability came in at $7.8 million in Q1 2026, up 6.24% year-on-year from $7.3 million in Q1 2025, and down 2.15% quarter-over-quarter from $8.0 million in Q4 2025.
uniQure (QURE) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
uniQure's Non-Current Deferred Tax Liability history runs 6 years deep, the most recent figure standing at $7.8 million for Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability rose 6.24% year-over-year to $7.8 million in Q1 2026; TTM through Mar 2026 was $7.8 million, a 6.24% increase from a year earlier, with the FY2025 full-year figure at $8.0 million, up 13.12% from the prior year.
- Non-Current Deferred Tax Liability fell to $7.8 million in Q1 2026 per QURE's latest filing, from $8.0 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $11.3 million in Q1 2022 and bottomed at $4.9 million in Q3 2023.
- The 5-year median for Non-Current Deferred Tax Liability is $7.6 million (2024), against an average of $7.8 million.
- Across the five-year window, Non-Current Deferred Tax Liability slumped 42.77% in 2023 and soared 55.11% in 2024, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $8.3 million in 2022, then slipped by 8.65% to $7.5 million in 2023, then decreased by 6.63% to $7.0 million in 2024, then climbed by 13.12% to $8.0 million in 2025, then decreased by 2.15% to $7.8 million in 2026.
- Per Business Quant, the three latest QURE Non-Current Deferred Tax Liability figures stand at $7.8 million (Q1 2026), $8.0 million (Q4 2025), and $8.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | uniQure | 2.47 Bn | 2.47 Bn | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.80 Mn |
| Mar 31, 2026 | 7.80 Mn |
| Dec 31, 2025 | 7.97 Mn |
| Dec 31, 2025 | 7.97 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | 7.96 Mn |
| Mar 31, 2025 | 7.34 Mn |
| Mar 31, 2025 | 7.34 Mn |
| Dec 31, 2024 | 7.04 Mn |
| Dec 31, 2024 | 7.04 Mn |
| Sep 30, 2024 | 7.63 Mn |
| Sep 30, 2024 | 7.63 Mn |
| Jun 30, 2024 | 7.32 Mn |
| Jun 30, 2024 | 7.32 Mn |
| Mar 31, 2024 | 7.38 Mn |
| Mar 31, 2024 | 7.38 Mn |
| Dec 31, 2023 | 7.54 Mn |
| Dec 31, 2023 | 7.54 Mn |